Cantor Fitzgerald Reaffirms “Buy” Rating for Shire PLC (SHPG)
Shire PLC (NASDAQ:SHPG)‘s stock had its “buy” rating reiterated by Cantor Fitzgerald in a research note issued on Monday.
Several other equities analysts have also commented on SHPG. Jefferies Group LLC reaffirmed a “hold” rating and issued a $206.00 price target (down previously from $216.00) on shares of Shire PLC in a research note on Wednesday, August 9th. Barclays PLC lowered Shire PLC from an “overweight” rating to an “equal weight” rating in a research note on Friday, August 11th. Sanford C. Bernstein reaffirmed a “market perform” rating and issued a $210.00 price target on shares of Shire PLC in a research note on Thursday, July 13th. BidaskClub lowered Shire PLC from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 5th. Finally, Evercore ISI assumed coverage on Shire PLC in a research note on Wednesday, August 16th. They issued an “outperform” rating and a $196.00 price target on the stock. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating and fifteen have assigned a buy rating to the company. Shire PLC presently has a consensus rating of “Buy” and an average price target of $220.08.
Shire PLC (SHPG) traded down 3.39% on Monday, hitting $140.62. The stock had a trading volume of 2,670,474 shares. Shire PLC has a 12 month low of $139.36 and a 12 month high of $209.22.
Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings results on Thursday, August 3rd. The biopharmaceutical company reported $3.73 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.53 by $0.20. Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. The business had revenue of $3.75 billion for the quarter. During the same period last year, the company earned $3.38 EPS. The business’s revenue for the quarter was up 54.2% on a year-over-year basis. On average, analysts expect that Shire PLC will post $14.91 EPS for the current year.
TRADEMARK VIOLATION WARNING: “Cantor Fitzgerald Reaffirms “Buy” Rating for Shire PLC (SHPG)” was published by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this report on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark legislation. The legal version of this report can be accessed at https://theolympiareport.com/2017/08/21/cantor-fitzgerald-reaffirms-buy-rating-for-shire-plc-shpg.html.
A number of large investors have recently modified their holdings of SHPG. HPM Partners LLC bought a new stake in shares of Shire PLC during the first quarter valued at $1,534,000. Vanguard Group Inc. increased its stake in shares of Shire PLC by 0.9% in the first quarter. Vanguard Group Inc. now owns 1,542,634 shares of the biopharmaceutical company’s stock valued at $268,773,000 after buying an additional 13,665 shares during the period. BlackRock Inc. increased its stake in shares of Shire PLC by 4,217.7% in the first quarter. BlackRock Inc. now owns 1,433,475 shares of the biopharmaceutical company’s stock valued at $249,755,000 after buying an additional 1,400,275 shares during the period. Laurion Capital Management LP bought a new stake in shares of Shire PLC during the first quarter valued at $10,611,000. Finally, Atria Investments LLC increased its stake in shares of Shire PLC by 32.6% in the second quarter. Atria Investments LLC now owns 1,648 shares of the biopharmaceutical company’s stock valued at $272,000 after buying an additional 405 shares during the period. Institutional investors own 20.22% of the company’s stock.
About Shire PLC
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.